DOCSLIB.ORG

SEER Program Coding and Staging Manual 2018

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
SEER Program Coding and Staging Manual 2018 SEER Program Coding and Staging Manual 2018 Effective with cases diagnosed January 1, 2018 Data Quality, Analysis, and Interpretation Branch Surveillance Research Program Division of Cancer Control and Population Sciences National Institutes of Health Public Health Service U.S. Department of Health and Human Services Suggested citation: Adamo M, Dickie L, Ruhl J. (January 2018). SEER Program Coding and Staging Manual 2018. National Cancer Institute, Bethesda, MD 20892. U.S. Department of Health and Human Services National Institutes of Health National Cancer Institute SEER Program Coding and Staging Manual 2018 SEER Program Coding and Staging Manual 2018 Acknowledgements Suzanne Adams, BS, CTR Information Management Services, Inc Judy Andrews BA, CTR SEER Georgia Cancer Registry Robin Billett, MA, CTR SEER Georgia Cancer Registry Carolyn Callaghan, BS, CTR SEER Seattle Cancer Registry Jacque Clarken, BS, CTR SEER Utah Cancer Registry Eileen Elido, CTR SEER Hawaii Cancer Registry Carmela Groves, RN, MS, CTR Westat, Inc. Stephanie Hill, MPH New Jersey State Cancer Registry Loretta Huston, BS, CTR SEER Utah Cancer Registry Tiffany Janes, BA, CTR SEER Seattle Cancer Registry Bobbi Jo Matt, BS, RHIT, CTR SEER Iowa Cancer Registry Patrick Nicolin, BA, CTR Detroit Metropolitan Cancer Registry Nektarios Pappas, MD, CTR SEER Louisiana Cancer Registry Lisa A. Pareti, BS, RHIT, CTR SEER Louisiana Cancer Registry Cathryn R. Phillips, BA, CTR SEER Connecticut Cancer Registry Elizabeth Ramirez-Valdez, CTR SEER New Mexico Cancer Registry Winny Roshala, BA, CTR SEER Greater California Cancer Registry Frances E. Ross, BA, CTR SEER Kentucky Cancer Registry Candis Sanders, BS, CTR SEER Georgia Cancer Registry Christina Schwarz, BA, CTR SEER Greater Bay Area Cancer Registry Steve Scoppa, BS Information Management Services, Inc Sheree Serrian, BBA, RN, CTR SEER Georgia Cancer Registry Laine Suggs, CTR SEER New Mexico Cancer Registry Taina Valone, RHIA, CTR SEER Greater California Cancer Registry Kacey Wigren, RHIT, CTR SEER Utah Cancer Registry Copyright Information: All material in this manual is in the public domain and may be reproduced or copied without permission. We do request that you use a source citation. Acknowledgements ii SEER Program Coding and Staging Manual 2018 Table of Contents Preface to the 2018 SEER Program Coding and Staging Manual 1 Effective Date 1 Summary of Changes 1 Submitting Questions 3 Collection and Storage of Date Fields 4 Transmission Instructions for Date Fields 4 SEER Site-Specific Factors 1 – 6 4 Introduction 5 SEER Program 5 SEER Coding And Staging Manual Contents 5 Reportability 6 Dates of Diagnosis/Residency 6 Reportable Diagnosis List 6 Diagnosis Prior to Birth 8 Disease Regression 8 Reportable Examples 8 Non-Reportable Examples 9 Instructions for Reporting Solid Tumors 9 Cases Diagnosed Clinically Are Reportable 9 Brain or CNS Neoplasms 9 Casefinding Lists 9 Ambiguous Terminology 10 How to Use Ambiguous Terminology for Case Ascertainment 11 Instructions for Hematopoietic and Lymphoid Neoplasms 13 Changing Information on the Abstract 14 Determining Multiple Primaries 15 Solid Tumors 15 Hematopoietic and Lymphoid Neoplasms 15 Transplants 15 Section I Basic Record Identification 17 SEER Participant 18 Patient ID Number 20 Record Type 21 SEER Record Number 22 SEER Coding System--Original 23 SEER Coding System--Current 24 Table of Contents iii SEER Program Coding and Staging Manual 2018 Section II Information Source 25 Type of Reporting Source 26 CoC Accredited Flag 29 Section III Demographic Information 30 First Name 31 Last Name 32 Place of Residence at Diagnosis 33 County 35 County at Diagnosis Geocode 1970/80/90 36 County at Diagnosis Geocode 2000 37 County at Diagnosis Geocode 2010 38 County at Diagnosis Analysis 39 Address at Diagnosis--State 40 State at Diagnosis Geocode 1970/80/90 41 State at Diagnosis Geocode 2000 42 State at Diagnosis Geocode 2010 43 Census Tract 2010 44 Census Tract Certainty 2010 45 Census Tract Poverty Indicator 47 Rural Urban Continuum 2013 48 Rural Urban Commuting Area--Tract Level 2000 49 Rural Urban Commuting Area--Tract-Level 2010 50 Urban Rural Indicator Code--Tract Level 2000 51 Urban Rural Indicator Code--Tract Level 2010 52 Birthplace--State 53 Birthplace--Country 54 Date of Birth 55 Date of Birth Flag 57 Place of Death--State 58 Place of Death--Country 59 Age at Diagnosis 60 Race 1, 2, 3, 4, 5 61 Race--NAPIIA 66 IHS Link 68 Spanish Surname or Origin 69 Computed Ethnicity 71 Computed Ethnicity Source 72 NHIA Derived Hispanic Origin 73 Table of Contents iv SEER Program Coding and Staging Manual 2018 Sex 74 Marital Status at Diagnosis 75 Primary Payer at Diagnosis 76 Section IV Description of this Neoplasm 78 Date of Diagnosis 79 Date of Diagnosis Flag 84 Sequence Number--Central 85 Primary Site 88 Laterality 92 Diagnostic Confirmation 95 Morphology 98 Histologic Type ICD-O-3 99 Behavior Code 101 Grade Clinical 104 Grade Pathological 105 Grade Post Therapy 106 Tumor Size--Clinical 107 Tumor Size--Pathologic 110 ICD-O-2 Conversion Flag 114 ICD-O-3 Conversion Flag 115 Section V Stage of Disease at Diagnosis 116 Stage Data Items 117 Lymphovascular Invasion 118 Mets at Diagnosis--Bone 124 Mets at Diagnosis--Brain 126 Mets at Diagnosis--Liver 128 Mets at Diagnosis--Lung 130 Mets at Diagnosis--Distant Lymph Node(s) 132 Mets at Diagnosis--Other 134 Extent of Disease Data Items 136 Extent of Disease Primary Tumor 137 Extent of Disease Regional Nodes 138 Extent of Disease Metastases 139 Summary Stage 140 Summary Stage 2018 141 Derived Summary Stage 2018 142 Section VI Stage-related Data Items 143 SEER Site-specific Factor 1 144 Table of Contents v SEER Program Coding and Staging Manual 2018 Additional Stage-related Data Items for 2018 145 Section VII First Course of Therapy 147 First Course of Therapy 148 Date Therapy Initiated 152 Date Therapy Initiated Flag 155 Treatment Status 156 Date of First Surgical Procedure 157 Date of First Surgical Procedure Flag 158 Date of Most Definitive Surgical Resection of the Primary Site 159 Date of Most Definitive Surgical Resection of the Primary Site Flag 160 Surgery of Primary Site 161 Surgical Margins of the Primary Site 163 Scope of Regional Lymph Node Surgery 165 Date of Sentinel Lymph Node Biopsy 169 Date of Sentinel Lymph Node Biopsy Flag 170 Sentinel Lymph Nodes Examined 171 Sentinel Lymph Nodes Positive 172 Date of Regional Lymph Node Dissection 174 Date of Regional Lymph Node Dissection Flag 175 Regional Nodes Positive 176 Regional Nodes Examined 179 Surgical Procedure of Other Site 182 Reason for No Surgery of Primary Site 184 Date Radiation Started 187 Date Radiation Started Flag 188 Radiation Treatment Modality--Phase I, II, III 189 Radiation External Beam Planning Technique--Phase I, II, III 190 Radiation Sequence With Surgery 193 Reason for No Radiation 195 Date Systemic Therapy Started 196 Date Systemic Therapy Started Flag 197 Date Chemotherapy Started 198 Date Chemotherapy Started Flag 199 Chemotherapy 200 Date Hormone Therapy Started 206 Date Hormone Therapy Started Flag 207 Hormone Therapy 208 Date Immunotherapy Started 211 Table of Contents vi SEER Program Coding and Staging Manual 2018 Date Immunotherapy Started Flag 212 Immunotherapy 213 Hematologic Transplant And Endocrine Procedures 216 Systemic Treatment/Surgery Sequence 219 Date Other Treatment Started 221 Date Other Treatment Started Flag 222 Other Therapy 223 Section VIII Follow Up Information 226 Death Clearance Instructions 227 Date of Last Follow-Up or of Death 228 Date of Last Follow-Up or Death Flag 231 Vital Status 232 ICD Code Revision Used for Cause of Death 233 Underlying Cause of Death 234 Type of Follow-Up 236 Survival Data Items 237 Section IX Administrative Codes 238 Site/Type Interfield Review 239 Histology/Behavior Interfield Review 240 Age/Site/Histology Interfield Review 241 Sequence Number/Diagnostic Confirmation Interfield Review 242 Site/Histology/Laterality/Sequence Interrecord Review 243 Surgery/Diagnostic Confirmation Interfield Review 244 Type of Reporting Source/Sequence Number Interfield Review 245 Sequence Number/Ill-Defined Site Interfield Review 246 Leukemia or Lymphoma/Diagnostic Confirmation Interfield Review 247 Over-ride Flag for Name/Sex 248 Over-ride Flag for Site/Behavior (IF39) 249 Over-ride Flag for Site/EOD/Diagnosis Date (IF40) 250 Over-ride Flag for Site/Laterality/EOD (IF41) 251 Over-ride Flag for Site/Laterality/Morphology (IF42) 252 Over-ride Flag for TNM Tis 253 Over-ride Flag for Site/TNM-Stage Group 254 Table of Contents vii SEER Program Coding and Staging Manual 2018 Preface to the 2018 SEER Program Coding and Staging Manual The 2018 Surveillance, Epidemiology and End Results (SEER) Program Coding and Staging Manual may be downloaded in electronic format from the SEER website: http://www.seer.cancer.gov/tools/codingmanuals. Effective Date The 2018 SEER Program Coding and Staging Manual is effective for cases diagnosed January 1, 2018 and forward. Previous editions of this manual are available on the SEER website. Summary of Changes Extent of Disease and Summary Stage Beginning in 2018, Extent of Disease (EOD) and Summary Stage data items are being incorporated into cancer staging. Site-Specific Data Items Data items formerly referred to as site-specific factors (SSFs) were assigned to specific cancer sites. SSFs have been transitioned to individual data items called site-specific data items (SSDIs) that can be utilized across cancer sites in 2018. Solid Tumor Rules The 2018 SEER Multiple Primary/Histology Rules are
Load more

Recommended publications
  • Is There Anything New in Prostate Cancer Screening?
    IS THERE ANYTHING NEW IN PROSTATE CANCER SCREENING? ANDREW M.D. WOLF, MD, FACP ASSOCIATE PROFESSOR OF MEDICINE UNIVERSITY OF VIRGINIA SCHOOL OF MEDICINE No financial disclosures Case Presentation 62 yo white man without significant past medical history presents for annual preventive visit. He has no family history of prostate cancer. He has mild urinary hesitancy and his prostate is mildly enlarged without induration or nodules. His PSA has been gradually rising: - 2011: 2.35 - 2013: 2.17 - 2017: 3.75 - 2019: 4.51 Where do we go from here? What’s New in Prostate Cancer Screening? Key Questions • Do we have any new evidence for or against screening? • Do we have anything better than the PSA? • What about the good old digital rectal exam? • Are we doing any better identifying who needs to be treated? • What do the experts recommend? Prostate Cancer Incidence & Mortality Over the Decades Source: Seer 9 areas & US Mortality Files (National Center for Health Statistics, CDC, Feb 2018 CA Cancer J Clin 2019;69:7-34. Do we have any new evidence for or against prostate cancer screening? Is Prostate Screening Still Controversial? ERSPC Results • Prostate cancer death rate 27% lower in screened group (p = 0.0001) at 13 yrs • Number needed to screen to save 1 life: 781 • NNS to prevent 1 case of metastatic cancer: ~350 • Number needed to diagnose to save 1 life: 27 • Major issue of over-diagnosis & over-treatment Schroder FH, et al. Lancet 2014;384: 2027–2035 • Controlled for differences in study design • Adjusted for lead-time • Both studies led to a ~ 25-32% reduction in prostate cancer mortality with screening compared with no screening Ann Intern Med 2017;167:449-455 • 415,000 British men 50-69 randomized to a single offer to screen vs usual care (info sheet on request) • One-time screen & then followed for 10 yrs • Men dx’d with prostate cancer randomized to treatment vs active surveillance JAMA 2018;319(9):883-895.
    [Show full text]
  • QUEST Provider Bulletin
    HMSA Provider Bulletin HMS A ’ S P L an fo R Q U E S T M embe R S Bulletin Q08-01 January 15, 2008 A MESSAGE FROM OUR appointments, ensuring the collection and forwarding of MEDICAL DIRECTOR necessary information, obtaining prior authorizations, educating the parents, and following up to ensure appointments are kept is Children with Special Health Care Needs guaranteed to be difficult and time consuming. Children with chronic illnesses are Other examples include children with diabetes, congenital heart challenging for pediatricians and other defects, seizure disorders, asthma, cancer (even if in remission), primary care providers entrusted with and juvenile rheumatoid arthritis. Also included are children their care. This is especially so for with multiple diagnoses, related or otherwise. those children whose management The Hawaii Department of Health has a service dedicated to requires the services of various assisting such children, their families and their caregivers. This medical specialists, allied health care is the Children with Special Health Needs Program, under the providers, organizations, and institutions. A child with Family Health Services Division. Children and youth under 21 a cleft palate, for example, may require the services of years of age residing in Hawaii are eligible if they have chronic an ENT surgeon, oral surgeon, dentist, audiologist, health conditions lasting (or expected to last) at least one year, speech therapist, DME provider (for hearing aids), for which specialized medical care is required. and the Department of Education. Locating these The Children with Special Health Needs Program can assist providers, making the necessary referrals, coordinating QUEST members who are having difficulty in coordinating or obtaining health care services, or who cannot obtain certain Happy New Year 2008 services through QUEST, with the following: IN THIS ISSUE: • Coordination of health care referrals and appointments.
    [Show full text]
  • Follicular Lymphoma
    Follicular Lymphoma What is follicular lymphoma? Let us explain it to you. www.anticancerfund.org www.esmo.org ESMO/ACF Patient Guide Series based on the ESMO Clinical Practice Guidelines FOLLICULAR LYMPHOMA: A GUIDE FOR PATIENTS PATIENT INFORMATION BASED ON ESMO CLINICAL PRACTICE GUIDELINES This guide for patients has been prepared by the Anticancer Fund as a service to patients, to help patients and their relatives better understand the nature of follicular lymphoma and appreciate the best treatment choices available according to the subtype of follicular lymphoma. We recommend that patients ask their doctors about what tests or types of treatments are needed for their type and stage of disease. The medical information described in this document is based on the clinical practice guidelines of the European Society for Medical Oncology (ESMO) for the management of newly diagnosed and relapsed follicular lymphoma. This guide for patients has been produced in collaboration with ESMO and is disseminated with the permission of ESMO. It has been written by a medical doctor and reviewed by two oncologists from ESMO including the lead author of the clinical practice guidelines for professionals, as well as two oncology nurses from the European Oncology Nursing Society (EONS). It has also been reviewed by patient representatives from ESMO’s Cancer Patient Working Group. More information about the Anticancer Fund: www.anticancerfund.org More information about the European Society for Medical Oncology: www.esmo.org For words marked with an asterisk, a definition is provided at the end of the document. Follicular Lymphoma: a guide for patients - Information based on ESMO Clinical Practice Guidelines – v.2014.1 Page 1 This document is provided by the Anticancer Fund with the permission of ESMO.
    [Show full text]
  • Profiling Prostate Cancer Therapeutic Resistance
    International Journal of Molecular Sciences Review Profiling Prostate Cancer Therapeutic Resistance Cameron A. Wade 1 and Natasha Kyprianou 1,2,3,* 1 Departments of Urology, University of Kentucky College of Medicine, Lexington, Kentucky, KY 40536, USA; [email protected] 2 Department of Molecular and Cellular Biochemistry, University of Kentucky College of Medicine, Lexington, Kentucky, KY 40536, USA 3 Department of Toxicology & Cancer Biology, University of Kentucky College of Medicine, Lexington, Kentucky, KY 40536, USA * Correspondence: [email protected]; Tel.: +1-859-323-9812; Fax: +1-859-323-1944 Received: 1 March 2018; Accepted: 16 March 2018; Published: 19 March 2018 Abstract: The major challenge in the treatment of patients with advanced lethal prostate cancer is therapeutic resistance to androgen-deprivation therapy (ADT) and chemotherapy. Overriding this resistance requires understanding of the driving mechanisms of the tumor microenvironment, not just the androgen receptor (AR)-signaling cascade, that facilitate therapeutic resistance in order to identify new drug targets. The tumor microenvironment enables key signaling pathways promoting cancer cell survival and invasion via resistance to anoikis. In particular, the process of epithelial-mesenchymal-transition (EMT), directed by transforming growth factor-β (TGF-β), confers stem cell properties and acquisition of a migratory and invasive phenotype via resistance to anoikis. Our lead agent DZ-50 may have a potentially high efficacy in advanced metastatic castration resistant prostate cancer (mCRPC) by eliciting an anoikis-driven therapeutic response. The plasticity of differentiated prostate tumor gland epithelium allows cells to de-differentiate into mesenchymal cells via EMT and re-differentiate via reversal to mesenchymal epithelial transition (MET) during tumor progression.
    [Show full text]
  • Radiation Therapy – a Technicians Overview By: Stephanie Corsi, CVT
    Radiation Therapy – A technicians overview By: Stephanie Corsi, CVT Senior Radiation Oncology nurse, PennVet What is radiation therapy? Radiation therapy uses high-energy radiation or high energy particle (electrons) to kill cancer cells and shrink tumors. How does radiation therapy work? Radiation kills cancer cells by damaging their DNA. Cells that are rapidly dividing, like cancer cells, are more susceptible to radiation. The damage is by a high energy photon ejecting a high energy electron that then reacts with a water molecule to create charged particle, also called free radicals, within the cell that will damage the DNA. Most cells die what is called a “mitotic death”, meaning the cancer cells whose DNA is damaged beyond repair will stop dividing and die. Goal of Radiation: The purpose of radiation is to maximize the likelihood of tumor control while minimizing side-effects to the patient. Radiation may be used alone or in combination with surgery, chemotherapy, or both. “Curative” intent/ definitive therapy: This is given when the prognosis is good. The hope is that treatment will cure a cancer by eliminating a tumor and preventing recurrence. For tumors that are inherently sensitive, relatively small, and localized. Also used to treat residual cancer left behind after surgery, or before surgery to shrink a tumor. Examples: localized lymphomas, certain mast cell tumors, cutaneous squamous cell carcinomas Palliative intent: Not intended to cure, but rather relieve symptoms and reduce suffering. Given when prognosis is poor and quality of life is the primary focus. Used with bulky tumors. Examples: alleviate bone pain associated with osteosarcoma, a tumor pressing on the spine, tumors pressing on the esophagus interfering with breathing/eating, etc.
    [Show full text]
  • Clinical Outcomes and Prognostic Factors of Cyberknife Stereotactic
    Que et al. BMC Cancer (2016) 16:451 DOI 10.1186/s12885-016-2512-x RESEARCH ARTICLE Open Access Clinical outcomes and prognostic factors of cyberknife stereotactic body radiation therapy for unresectable hepatocellular carcinoma Jenny Que1*, Hsing-Tao Kuo2, Li-Ching Lin1, Kuei-Li Lin1, Chia-Hui Lin1, Yu-Wei Lin1 and Ching-Chieh Yang1 Abstract Background: Stereotactic body radiation therapy (SBRT) has been an emerging non-invasive treatment modality for patients with hepatocellular carcinoma (HCC) when curative treatments cannot be applied. In this study, we report our clinical experience with Cyberknife SBRT for unresectable HCC and evaluate the efficacy and clinical outcomes of this highly sophisticated treatment technology. Methods: Between 2008 and 2012, 115 patients with unresectable HCC treated with Cyberknife SBRT were retrospectively analyzed. Doses ranged from 26 Gy to 40 Gy were given in 3 to 5 fractions for 3 to 5 consecutive days. The cumulative probability of survival was calculated according to the Kaplan-Meier method and compared using log-rank test. Univariate and multivariate analysis were performed using Cox proportional hazard models. Results: The median follow-up was 15.5 months (range, 2-60 months). Based on Response Evaluation and Criteria inSolidTumors(RECIST).Wefoundthat48.7%ofpatients achieved a complete response and 40 % achieved a partial response. Median survival was 15 months (4-25 months). Overall survival (OS) at 1- and 2-years was 63. 5 %(54-71.5 %) and 41.3 % (31.6-50.6 %), respectively, while 1- and 2- years Progression-free Survival (PFS) rates were 42.8 %(33.0-52.2 %) and 38.8 % (29.0-48.4 %).
    [Show full text]
  • New Source of Black Rot Disease Resistance in Brassica Oleracea and Genetic Analysis of Resistance
    Euphytica (2016) 207:35–48 DOI 10.1007/s10681-015-1524-y New source of black rot disease resistance in Brassica oleracea and genetic analysis of resistance Partha Saha . Pritam Kalia . Munish Sharma . Dinesh Singh Received: 1 May 2015 / Accepted: 22 July 2015 / Published online: 28 July 2015 Ó Springer Science+Business Media Dordrecht 2015 Abstract Black rot is the most widespread and Himjyoti x BR-207) and (Pusa Sharad x BR-207) were devastating disease in Brassica oleracea crops. The evaluated. Segregation ratios obtained were compared objective of this work was to identify new sources of by Chi square test at 5 % probability. The F1 resistance to races 1 and 4 of Xcc in 46 B. oleracea generations were resistant and segregation ratio of accessions and to understand genetics of resistance. resistant and susceptible plants indicated 3(R):1(S) in Most of the accessions were susceptible to both the F2 and 1(R):2 (Seg):1(S) in F3 which suggested that races, except accessions BR-207, BR-1, BR-202-2 and resistance to Xcc race 1 in BR-207 is governed by a AL-15 of botrytis group to Xcc race 1. The partial single dominant gene. The information obtained in this resistant plants were observed in some accessions BR- study could be valuable for black rot resistance 202-2 (90 % plants) and AL-27 (10 % plants) of breeding and in planning a systematic breeding botrytis, DJ8012 (20 % plants) of capitata, 005426 programme to incorporate the black rot resistance (10 % plants) of italica. All the accessions were into the susceptible cultivars.
    [Show full text]
  • Guidelines on Paediatric Urology S
    Guidelines on Paediatric Urology S. Tekgül (Chair), H.S. Dogan, E. Erdem (Guidelines Associate), P. Hoebeke, R. Ko˘cvara, J.M. Nijman (Vice-chair), C. Radmayr, M.S. Silay (Guidelines Associate), R. Stein, S. Undre (Guidelines Associate) European Society for Paediatric Urology © European Association of Urology 2015 TABLE OF CONTENTS PAGE 1. INTRODUCTION 7 1.1 Aim 7 1.2 Publication history 7 2. METHODS 8 3. THE GUIDELINE 8 3A PHIMOSIS 8 3A.1 Epidemiology, aetiology and pathophysiology 8 3A.2 Classification systems 8 3A.3 Diagnostic evaluation 8 3A.4 Disease management 8 3A.5 Follow-up 9 3A.6 Conclusions and recommendations on phimosis 9 3B CRYPTORCHIDISM 9 3B.1 Epidemiology, aetiology and pathophysiology 9 3B.2 Classification systems 9 3B.3 Diagnostic evaluation 10 3B.4 Disease management 10 3B.4.1 Medical therapy 10 3B.4.2 Surgery 10 3B.5 Follow-up 11 3B.6 Recommendations for cryptorchidism 11 3C HYDROCELE 12 3C.1 Epidemiology, aetiology and pathophysiology 12 3C.2 Diagnostic evaluation 12 3C.3 Disease management 12 3C.4 Recommendations for the management of hydrocele 12 3D ACUTE SCROTUM IN CHILDREN 13 3D.1 Epidemiology, aetiology and pathophysiology 13 3D.2 Diagnostic evaluation 13 3D.3 Disease management 14 3D.3.1 Epididymitis 14 3D.3.2 Testicular torsion 14 3D.3.3 Surgical treatment 14 3D.4 Follow-up 14 3D.4.1 Fertility 14 3D.4.2 Subfertility 14 3D.4.3 Androgen levels 15 3D.4.4 Testicular cancer 15 3D.5 Recommendations for the treatment of acute scrotum in children 15 3E HYPOSPADIAS 15 3E.1 Epidemiology, aetiology and pathophysiology
    [Show full text]
  • 35°C—47°C Today D
    Community Community Bazm-e-Sadaf Chaliyar Doha International’s observes P7evening for Urdu P16 World lovers is attended Environment Day by Doha-based in association writers and with embassy of poets. India. Sunday, June 10, 2018 Ramadan 25, 1439 AH DOHA 35°C—47°C TODAY PUZZLES 12 & 13 LIFESTYLE/HOROSCOPE 14 Incredible journey Bollywood yesteryear star COVER Kajol on her journey and STORY the latest ventures. P4-5 2 GULF TIMES Sunday, June 10, 2018 COMMUNITY ROUND & ABOUT PRAYER TIME Fajr 3.14am Shorooq (sunrise) 4.43am Zuhr (noon) 11.33am Asr (afternoon) 2.56pm Maghreb (sunset) 6.27pm Isha (night) 7.57pm USEFUL NUMBERS Kaala lead role, while Nana Patekar, Samuthirakani, Easwari Rao DIRECTION: Pa. Ranjith portray the supporting roles. Music is composed by Santhosh CAST: Rajinikanth, Huma Qureshi, Nana Patekar Narayanan. Kaala who runs away from Tirunelveli in his SYNOPSIS: Kaala is an upcoming Indian Tamil political childhood, moves to Mumbai where he becomes a powerful gangster movie written and directed by Pa Ranjith and don living in the slums of Dharavi. produced by Dhanush. The fi lm stars Rajinikanth in the THEATRES: The Mall, Royal Plaza, Landmark Emergency 999 Worldwide Emergency Number 112 Kahramaa – Electricity and Water 991 Local Directory 180 International Calls Enquires 150 Hamad International Airport 40106666 Labor Department 44508111, 44406537 Mowasalat Taxi 44588888 Qatar Airways 44496000 Hamad Medical Corporation 44392222, 44393333 Qatar General Electricity and Water Corporation 44845555, 44845464 Primary Health Care Corporation 44593333 44593363 Qatar Assistive Technology Centre 44594050 Qatar News Agency 44450205 44450333 Q-Post – General Postal Corporation 44464444 Humanitarian Services Offi ce (Single window facility for the repatriation of bodies) Ministry of Interior 40253371, 40253372, 40253369 Ministry of Health 40253370, 40253364 Hamad Medical Corporation 40253368, 40253365 Qatar Airways 40253374 Jurassic World: Fallen Kingdom destruction of the Jurassic World theme soon encounter terrifying new breeds DIRECTION: J.
    [Show full text]
  • Updates in Assessment of the Breast After Neoadjuvant Treatment
    Updates in Assessment of The Breast After Neoadjuvant Treatment Laila Khazai 3/3/18 AJCC, 8th Edition AJCC • Pathologic Prognostic Stage is not applicable for patients who receive neoadjuvant therapy. • Pathologic staging includes all data used for clinical staging, plus data from surgical resection. • Information recorded should include: – Clinical Prognostic Stage. – The category information for either clinical (ycT and ycN) response to therapy if surgery is not performed, or pathologic (ypT and ypN) if surgery is performed. – Degree of response (complete, partial, none). AJCC • Post -treatment size should be estimated based on the best combination of imaging, gross, and microscopic histological findings. • The ypT is determined by measuring the largest single focus of residual invasive tumor, with a modifier (m) indicating multiple foci of residual tumor. • This measurement does not include areas of fibrosis within the tumor bed. • When the only residual cancer intravascular or intralymphatic (LVI), the yPT0 category is assigned, but it is not classified as complete pathologic response. A formal system (i.e. RCB, Miller-Payne, Chevalier, …) may be offered in the report. Otherwise, description of the distance over which tumor foci extend, the number of tumor foci present, or the number of tumor slides/blocks in which tumor appears might be offered. AJCC • The ypN categories are the same as those used for pN. • Only the largest contiguous focus of residual tumor is used for classification (treatment associated fibrosis is not included). • Inclusion of additional information such as distance over which tumor foci extend and the number of tumor foci present, may assist the clinician in estimating the extent of residual disease.
    [Show full text]
  • The Updated AJCC/TNM Staging System (8Th Edition) for Oral Tongue Cancer
    166 Editorial The updated AJCC/TNM staging system (8th edition) for oral tongue cancer Kyubo Kim, Dong Jin Lee Department of Otorhinolaryngology-Head and Neck Surgery, Hallym University College of Medicine, Seoul, South Korea Correspondence to: Dong Jin Lee, MD, PhD. 1 Singil-ro, Yeongdeungpo-gu, Seoul 150-950, South Korea. Email: [email protected]. Comment on: Almangush A, Mäkitie AA, Mäkinen LK, et al. Small oral tongue cancers (≤ 4 cm in diameter) with clinically negative neck: from the 7th to the 8th edition of the American Joint Committee on Cancer. Virchows Arch 2018;473:481-7. Submitted Dec 22, 2018. Accepted for publication Dec 28, 2018. doi: 10.21037/tcr.2019.01.02 View this article at: http://dx.doi.org/10.21037/tcr.2019.01.02 An increasing amount of literature shows solid evidence that updated classification system and the applicability of DOI as the depth of invasion (DOI) of oral cavity squamous cell a predictor of clinical behavior for early-stage OTSCC. carcinoma is an independent predictor for occult metastasis, The AJCC 8th edition employs a cut-off value of 5 mm recurrence, and survival (1-3). Furthermore, the DOI of the DOI for upstaging from stage T1 to T2 and 10 mm for primary tumor has been a major criterion when deciding to upstaging to T3. This may be questionable as it has been perform elective neck dissection on oral cavity squamous shown that an invasion depth of more than 4 mm increases cell carcinoma patients since as early as the mid-1990s (4). the risk of locoregional metastasis and is associated with a A cut-off value of 4 mm has conventionally been used poor prognosis (9-11), but with the new staging system, a when determining the need for elective neck dissection, large number of invasive tumors in which the DOI is less based on a study by Kligerman et al.
    [Show full text]
  • Endocrine Surgery Goals and Objectives
    Lenox Hill Hospital Department of Surgery Endocrine Surgery Goals and Objectives Medical Knowledge and Patient Care: Residents must demonstrate knowledge and application of the pathophysiology and epidemiology of the diseases listed below for this rotation, with the pertinent clinical and laboratory findings, differential diagnosis and therapeutic options including preventive measures, and procedural knowledge. They must show that they are able to gather accurate and relevant information using medical interviewing, physical examination, appropriate diagnostic workup, and use of information technology. They must be able to synthesize and apply information in the clinical setting to make informed recommendations about preventive, diagnostic and therapeutic options, based on clinical judgement, scientific evidence, and patient preferences. They should be able to prescribe, perform, and interpret surgical procedures listed below for this rotation. All Residents are expected to understand: 1. Normal physiology and anatomy of the thyroid glands. 2. Normal physiology and anatomy of the parathyroid glands. 3. Normal physiology and anatomy of the adrenal glands 4. Normal physiology of the pancreatic neuroendocrine cells. 5. Normal physiology of the pituitary gland. Disease-Based Learning Objectives: Hyperfunctioning Thyroid and Hypothyroid State: 1. Physiology of Grave’s disease and toxic goiter. 2. Management of a patient in hyperthyroid storm. 3. Medical and surgical treatment options for hyperthyroidism. 4. Physiology of Hashimoto’s thyroiditis and hypothyroidism. Thyroid Neoplasm: 1. Workup of a cold thyroid nodule. 2. Surgical management of papillary, follicular, medullary, and anaplastic thyroid carcinoma. 3. Adjuvant therapy for thyroid neoplasms. 4. Postoperative medical management and long-term follow-up of thyroid cancer. Hyperparathyroidism: 1. Diagnosis and work-up of hypercalcemia and primary, secondary, and tertiary hyperparathyroidism.
    [Show full text]